Navigation of each product type

Our recommended contents

Our recommended contents

Here begins the text.

MHLW Pharmaceuticals and Medical Devices Safety Information (FY2021)

FY 2021 (No.382-)

Japanese version issued on	No.	Table of contents	Posted on	PDF
April 27, 2021	382	PI (Package insert)-navi: A Smartphone App Designed for Digitized Package Inserts Digitization of Reports from Medical Institutions on Adverse Drug Reactions and Post-vaccination Suspected Adverse Reactions Important Safety Information Ritodrine hydrochloride (injections) Durvalumab (genetical recombination) Onasemnogene abeparvovec Revision of Precautions (No. 322) Magnesium sulfate hydrate/glucose (preparations indicated for prophylaxis and treatment of eclampsia in severe hypertensive disorders of pregnancy) (and 8 others) List of Products Subject to Early Post-marketing Phase Vigilance	Apr 27, 2021	(Full text)

Pmda - Pharmaceuticals and Medical Devices Agency

JCN 3010005007409

Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki,
Chiyoda-ku, Tokyo 100-0013 Japan